Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives
In the last couple of decades substantial therapeutic improvements deeply influenced the treatment of HER2-positive metastatic breast cancer. The most impactful advancements were obtained especially in the first-line setting, with the trastuzumab/pertuzumab anti-HER2 double blockade, and in the seco...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Heliyon |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023105755 |
| _version_ | 1797337039616606208 |
|---|---|
| author | Francesco Schettini Fabiola Giudici Daniele Generali |
| author_facet | Francesco Schettini Fabiola Giudici Daniele Generali |
| author_sort | Francesco Schettini |
| collection | DOAJ |
| description | In the last couple of decades substantial therapeutic improvements deeply influenced the treatment of HER2-positive metastatic breast cancer. The most impactful advancements were obtained especially in the first-line setting, with the trastuzumab/pertuzumab anti-HER2 double blockade, and in the second line, with the advent of the potent antibody-drug conjugate trastuzumab deruxtecan. Nevertheless, a careful observation of the patterns of early-progression and long-term effects on overall survival of the most novel agents and combinations, highlights the challenges represented by the emergence of therapeutic resistance and optimal drug sequencing. The integration of sequence studies, tumor-related biomarker development/implementation and understanding of primary mechanisms of resistance to novel anti-HER2 agents, will be the way to move forward to effectively tackle these novel unmet needs. |
| first_indexed | 2024-03-08T09:03:37Z |
| format | Article |
| id | doaj.art-85912a339b0a4254bffe9d44c44830ba |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-08T09:03:37Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-85912a339b0a4254bffe9d44c44830ba2024-02-01T06:31:36ZengElsevierHeliyon2405-84402024-01-01101e23367Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectivesFrancesco Schettini0Fabiola Giudici1Daniele Generali2Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clínic of Barcelona, Barcelona, Spain; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain; Corresponding author. Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors Group, IDIBAPS, Faculty of Medicine, University of Barcelona C. Casanova 143, 08036, Barcelona, Spain.Breast Unit, Division of General Surgery, Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, Trieste, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy; Corresponding author. Department of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume 447, 34149, Trieste, Italy.In the last couple of decades substantial therapeutic improvements deeply influenced the treatment of HER2-positive metastatic breast cancer. The most impactful advancements were obtained especially in the first-line setting, with the trastuzumab/pertuzumab anti-HER2 double blockade, and in the second line, with the advent of the potent antibody-drug conjugate trastuzumab deruxtecan. Nevertheless, a careful observation of the patterns of early-progression and long-term effects on overall survival of the most novel agents and combinations, highlights the challenges represented by the emergence of therapeutic resistance and optimal drug sequencing. The integration of sequence studies, tumor-related biomarker development/implementation and understanding of primary mechanisms of resistance to novel anti-HER2 agents, will be the way to move forward to effectively tackle these novel unmet needs.http://www.sciencedirect.com/science/article/pii/S2405844023105755 |
| spellingShingle | Francesco Schettini Fabiola Giudici Daniele Generali Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives Heliyon |
| title | Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives |
| title_full | Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives |
| title_fullStr | Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives |
| title_full_unstemmed | Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives |
| title_short | Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives |
| title_sort | therapeutic resistance and optimal drug sequencing in her2 positive metastatic breast cancer unmet needs and future perspectives |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023105755 |
| work_keys_str_mv | AT francescoschettini therapeuticresistanceandoptimaldrugsequencinginher2positivemetastaticbreastcancerunmetneedsandfutureperspectives AT fabiolagiudici therapeuticresistanceandoptimaldrugsequencinginher2positivemetastaticbreastcancerunmetneedsandfutureperspectives AT danielegenerali therapeuticresistanceandoptimaldrugsequencinginher2positivemetastaticbreastcancerunmetneedsandfutureperspectives |